Kane Biotech Inc. · TSXV:KNE
Kane Biotech — Investor Presentation (December 2024)
20 slides from Kane Biotech's investor presentation, December 2024
Slide 1: Corporate Presentation
Corporate Presentation T S X - V: K N E OTC Q B : K N B I F December, 2024
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, which are made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties which could cause the Company's
Slide 3: Kane Biotech is THE Biofilm Company
Kane Biotech is THE Biofilm Company Leading the advancement of technologies and products that break up biofilms and destroy bacteria 3
Slide 4: Capitalization Overview
Capitalization Overview Share Summary Listing: TSX-V:KNE, OTCQB:KNBIF Stock Price: $0.12 52 Week Range: $0.05-0.17 Market Cap: $20M Shares Outstanding: 132.5M Ownership: Renaud Family & Management 54%; Other 46% 4
Slide 5: The Biofilm Problem
The Biofilm Problem Biofilm impaired healing is the largest unresolved problem in Wound Care The Centers for Disease Control and Prevention (CDC) has Biofilms are a glue-like substance identified resistant bacteria, which biofilms are a major excreted by bacteria that… contributor, as being a seriou
Slide 6: US FDA 510(k) cleared, reimbursed, growing distribution
✅US FDA 510(k) cleared ✅Reimbursed by Medicare and Medicaid ✅Growing Global Distribution Network ✅Commercial scale-up manufacturing complete The hydrogel dressing market in the U.S. was estimated at USD $258 million in 2022
Slide 7: Reasons to Invest
REASONS TO INVEST Commercializing with a pipeline 3 Robust pipeline of new products 2 Near-term catalysts 1 Proven technology Clinical Trial H1 2025 generating revenue today WOUND GEL Commercialized H2 2024 H2 2025 Clinical Trial H2 2024 H1 2026 SKIN CLEANSER WOUND CLEANSER Acquisition of H2 2024 7
Slide 8: Near Term Catalysts
Near Term Catalysts Spray: H2 2024 Surgical: H1 2025 Cleanser: H1 2026 • Leverages existing FDA • Leverages existing pre-clinical • Leverages existing pre-clinical Clearance testing, accelerating FDA testing, accelerating FDA • New propellant-free, bag- Clearance Clearance on-valve application • Ste
Slide 9: Growing Distribution Network
Signed agreements in UAE and Qatar. 1 Saudi Arabia, Kuwait, Oman, Bahrain pending. Growing Distribution Network 2 Commercialized through acquisition of FB Dermatology 2 1 2 2
Slide 10: Proven Technologies: coactiv+ and DispersinB
Proven Technologies Setting a New Standard in Biofilm Treatment coactiv+ Derived From GRAS Ingredients A Naturally Occurring Enzyme Kane Biotech’s patented coactiv+ technology is Kane Biotech’s patented, antibiofilm specifically formulated to destabilize biofilm with DispersinB® technology has demon
Slide 11: Robust Pipeline DispersinB
Robust Pipeline DispersinB® THE Missing Link in Wound Care. • Pursuing PMA Pathway - Allow for DispersinB® to become the first product to receive biofilm related claims and obtain a new reimbursement code for a higher price point Significantly Accelerated Healing of Wounds Compared to Controls in Pr
Slide 12: How Biofilms Lead to Acne
How Biofilms Lead to Acne DispersinB® Biofilm model of acne follicular anaerobiosis • Acne is a significant problem for millions of people with the global acne treatment market S. epidermidis determined at USD $9.36 billion in 2022 • DispersinB destroys S. epidermidis PNAG biofilm plug providing acc
Slide 13: Management
Management Dr. Robert Huizinga Marc Edwards Executive Chair President, CEO, Director Dr. Huizinga joined KANE Mr. Edwards was appointed Biotech in February 2024 and as the President and CEO of is also currently the principal the Corporation on of Reformation Consulting September 10, 2018. He is the
Slide 14: What is FB Dermatology?
What is it? • Italian-based biotechnology created by Francesco Bellini (BioChem Pharma, Bellus Health) with expertise in Fluorescent Light Energy (FLE) for advanced wound care, dermatology and aesthetics • Operations in Europe and Australia/New Zealand • ~$2M in product sales • Three main products:
Slide 15: Corporate Synergies
Corporate Synergies • Accelerated commercialization of revyveTM Antimicrobial Wound Gel internationally including Australia and New Zealand. • FB Dermatology’s sales and distribution networks in Europe, Australia and New Zealand will launch Kane’s DermaKBTM scalp care product line. • Commercial laun
Slide 16: Opportunity – Wound Care
Opportunity – Wound Care Technology Product Regulatory Status Opportunity Estimated global annual revenue revyve Antimicrobial Wound Gel $50M USD FDA 510(k) Cleared Strong appeal in burns, battlefield revyve Antimicrobial Wound Gel Health Canada Approved wounds and Emergency Medical Spray Services.
Slide 17: Opportunity – Dermatology
Opportunity – Dermatology Technology Product Regulatory Status Opportunity Estimated global annual market for DispersinB DispersinB Skin Cleanser Proof of Concept Trial 2025 acne $9.3B Estimated global annual market for Kleresca EMA: CE Mark acne FLE Tech $9.3B Lumixa Non-regulated Current annual re
Slide 18: Conclusion
Conclusion Q4 2024 ❑Financing announcement ❑Potential M&A announcement Proven technology ❑Announce distribution agreements generating revenue today outside of North America ❑Obtain clearance from Health Canada on revyve Antimicrobial Wound Gel Near-term catalysts and ❑Launch revyve Antimicrobial Wou
Slide 19: Contact Information
Contact Information: Marc Edwards, Chief Executive Officer Ray Dupuis, Chief Financial Officer medwards@kanebiotech.com rdupuis@kanebiotech.com C: (514) 910-6991 C: (204) 298-2200 KANEBIOTECH.COM 19
Slide 20: Kane Biotech Company Timeline: 2023 - 2025
Q1 Q2 Q4 Q1 Q3 Q4 Q4 Q2 Signed Signed exclusive Launch of Presenting Obtain MDSAP Commence Presenting 510(k) submission to distribution U.S. distribution newly branded sponsor at Certification DispersinB acne sponsor at FDA on sterile surgical agreement with agreement with revyve Boswick Burn & clin